+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Chemotherapy Treatment Market 2019-2023 - Product Image

Global Chemotherapy Treatment Market 2019-2023

  • ID: 4771149
  • Report
  • May 2019
  • Region: Global
  • 136 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Novartis AG
  • Pfizer Inc.
  • MORE
About this market

The recent approvals of chemotherapeutics to treat cancer is one of the key factors expected to trigger the chemotherapy treatment market during the forecast period. With the rising prevalence of cancer, the demand for chemotherapeutics agents is increasing. The market has witnessed recent approvals of chemotherapeutics agents such as TECENTRIQ by regulatory authorities in different regions. TECENTRIQ in combination with carboplatin and etoposide is being used for first-line treatment of adult patients with extensive-stage, small-cell lung cancer. This will boost the chemotherapy treatment market growth during the forecast period. The analysts have predicted that the chemotherapy treatment market will register a CAGR of nearly 3% by 2023.

Market Overview

Availability of drugs to treat the side-effects of chemotherapy

The drugs used in chemotherapy for cancer treatment have several side-effects such as vomiting and nausea, hypersensitivity reactions, and neutropenia. Hence, the availability of drugs to treat these side-effects will drive the growth of the market during the forecast period.

Emerging targeted therapies

The market has witnessed the development and approval of targeted therapies to treat different cancers, such as prostate cancer, lung and bronchus cancer, and thyroid cancer. This may pose a challenge to the global chemotherapy treatment market.

For the detailed list of factors that will drive and challenge the growth of the chemotherapy treatment market during 2019-2023, view the full report.

Competitive Landscape

The market appears to be moderately concentrated with the presence of a few market players. Several vendors in the market are focusing on the development of combination therapies with chemotherapy drugs along with targeted therapies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Novartis AG
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY DRUG CLASS
  • Market segmentation by drug class
  • Comparison by drug class
  • Antimetabolites - Market size and forecast 2018-2023
  • Plant derivatives - Market size and forecast 2018-2023
  • Cytotoxic antibiotics - Market size and forecast 2018-2023
  • Alkylating agents - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by drug class
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Market trends
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Combination therapy approvals
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Drug class - Market share 2018-2023 (%)
Exhibit 19: Comparison by drug class
Exhibit 20: Antimetabolites - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antimetabolites - Year-over-year growth 2019-2023 (%)
Exhibit 22: Plant derivatives - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Plant derivatives - Year-over-year growth 2019-2023 (%)
Exhibit 24: Cytotoxic antibiotics - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Cytotoxic antibiotics - Year-over-year growth 2019-2023 (%)
Exhibit 26: Alkylating agents - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Alkylating agents - Year-over-year growth 2019-2023 (%)
Exhibit 28: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Others - Year-over-year growth 2019-2023 (%)
Exhibit 30: Market opportunity by drug class
Exhibit 31: Customer landscape
Exhibit 32: Market share by geography 2018-2023 (%)
Exhibit 33: Geographic comparison
Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: North America - Year-over-year growth 2019-2023 (%)
Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Approvals of chemotherapeutics
Exhibit 45: Side-effects of chemotherapy drugs
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Combination therapies under late-stage clinical trials
Exhibit 48: Repurposed chemotherapy agents
Exhibit 49: Antibody drug conjugates undergoing clinical trials
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 56: Bristol-Myers Squibb Co. - Business segments
Exhibit 57: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 58: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 59: Bristol-Myers Squibb Co. - Key offerings
Exhibit 60: Eli Lilly and Co. - Vendor overview
Exhibit 61: Eli Lilly and Co. - Business segments
Exhibit 62: Eli Lilly and Co. - Organizational developments
Exhibit 63: Eli Lilly and Co. - Geographic focus
Exhibit 64: Eli Lilly and Co. - Segment focus
Exhibit 65: Eli Lilly and Co. - Key offerings
Exhibit 66: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 67: Johnson & Johnson Services Inc. - Business segments
Exhibit 68: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 69: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 70: Johnson & Johnson Services Inc. - Segment focus
Exhibit 71: Johnson & Johnson Services Inc. - Key offerings
Exhibit 72: Novartis AG - Vendor overview
Exhibit 73: Novartis AG - Business segments
Exhibit 74: Novartis AG - Organizational developments
Exhibit 75: Novartis AG - Geographic focus
Exhibit 76: Novartis AG - Segment focus
Exhibit 77: Novartis AG - Key offerings
Exhibit 78: Pfizer Inc. - Vendor overview
Exhibit 79: Pfizer Inc. - Business segments
Exhibit 80: Pfizer Inc. - Organizational developments
Exhibit 81: Pfizer Inc. - Geographic focus
Exhibit 82: Pfizer Inc. - Segment focus
Exhibit 83: Pfizer Inc. - Key offerings
Exhibit 84: Validation techniques employed for market sizing
Exhibit 85: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Novartis AG
  • Pfizer Inc.
  • MORE
Global Chemotherapy Treatment Market 2019-2023

The analyst recognizes the following companies as the key players in the global chemotherapy treatment market: Bristol-Myers Squibb Co., Eli Lilly and Co., Johnson & Johnson Services Inc., Novartis AG, and Pfizer Inc.

Commenting on the report, an analyst from the team said: “The latest trend gaining momentum in the market is the repurposing of existing chemotherapy agents.”

According to the report, one of the major drivers for this market is the availability of drugs to treat the side-effects of chemotherapy.

Further, the report states that one of the major factors hindering the growth of this market is the increasing genericization of chemotherapeutics.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll